InvestorsHub Logo
Followers 5387
Posts 51347
Boards Moderated 10
Alias Born 09/19/2006

Re: georgie18 post# 783

Tuesday, 04/21/2020 7:32:20 AM

Tuesday, April 21, 2020 7:32:20 AM

Post# of 853
$SCYX SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) GlobeNewswire "Press Releases"
Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpoints
Ibrexafungerp was generally safe and well-tolerated
Positive results consistent with previously reported VANISH-303 study support anticipated NDA submission for the treatment of vulvovaginal candidiasis (VVC) in the second half of 2020
Enrollment is ongoing in the CANDLE Phase 3 study of oral ibrexafungerp for the prevention of recurrent VVC, with supplemental NDA submission planned for the second half of 2021
Conference call to be held April 21 st, 2020 at 8:30 a.m. E

More Millionaires are made from penny stocks.

Give me a follow and you could be too~


Click Here: https://investorshub.advfn.com/boards/profilea.aspx?user=82434

All my posts are my opinion only! Do your DD!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SCYX News